• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delpor doses first patient in once-yearly risperidone implant trial

April 22, 2021 By Sean Whooley

Delpor DLP-114 Implant
The DLP-114 implant [image from Delpor]
Delpor announced today that it dosed the first patient in a Phase 1b/2a clinical trial for its DLP-114 risperidone implant.

DLP-114 is a long-acting formulation of the antipsychotic risperidone for schizophrenia maintenance therapy. The open-label study is to evaluate the safety, tolerability and pharmacokinetics of switching from oral risperidone to the once- or twice-yearly DLP-114 risperidone implant, according to a news release.

Brisbane, Calif.-base Delpor already completed a Phase 1 trial in healthy subjects to test the safety, tolerability and pharmacokinetics of DLP-114. The second trial will evaluate the switch from 2 mg/day or 3 mg/day oral risperidone to two implants over a six- or 12-month dosing period. The trial is in collaboration with the National Institute of Mental Health.

Delpor’s Prozor technology is designed to enable the sustained release of drugs from a non-mechanical, matchstick-long, implantable drug delivery device implanted in the abdomen during a 10-minute in-office procedure. The implant can be easily removed within minutes if required, too.

The implant is designed to deliver therapeutic levels of the drug for as long as one year, with potential benefits including reduced relapses due to medication adherence and a steady drug release that reduces adverse events like peaks or sub-therapeutic troughs.

“The dosing of the first patient in our Phase 1b/2a clinical trial is an important milestone for Delpor and our lead asset, DLP-114,” Delpor president & CEO Tassos Nicolaou said in the release. “Medication adherence is a significant challenge for patients with chronic conditions. Using Delpor’s proprietary Prozor technology, we’ve created DLP-114, a once-yearly, or twice-yearly risperidone implant that has the potential to significantly advance treatment outcomes for individuals with schizophrenia by improving medication adherence, and delivering a “smooth” pharmacokinetic profile resulting in enhanced safety and tolerability.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: delpor

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS